|
Diphtheria |
Corynebacterium diphtheriae |
Guinea pigs became protected |
[45] |
|
Foot-and-mouth disease |
Foot-and-mouth disease virus |
Neutralising antibodies induced in rabbits and guinea pigs |
[46] |
|
Foot-and-mouth disease |
Foot-and-mouth disease virus |
Cattle became protected |
[47] |
|
Malaria |
Plasmodium berghei |
Mice became protected |
[38] |
|
Gastroenteritis |
Simian rotavirus |
Neutralising antibodies induced in rabbits |
[48] |
|
Acquired immune deficiency syndrome |
Human immunodeficiency virus |
Neutralising antibodies induced in rabbits |
[49] |
First multi-epitope synthetic antimalarial vaccine |
Malaria |
Plasmodium falciparum |
Aotus monkeys became protected |
[39] |
SPf66 |
Malaria |
Plasmodium falciparum |
Humans became protected |
[11] |
SPf66 |
Malaria |
Plasmodium falciparum |
Safe and highly-immunogenic in humans |
[50,51,52] |
SPf66 |
Malaria |
Plasmodium falciparum |
Protective efficacy (30–40%) in semi-immune populations |
[12,53,54,55] |
|
Haemorrhagic enteritis, Myocarditis |
Canine parvovirus |
Dogs became protected |
[56] |
|
Malaria |
Plasmodium vivax |
Parasite development in the mosquito was blocked |
[57] |
|
Anthrax |
Bacillus anthracis |
Rabbit became protected |
[58] |
Fusion peptide |
Influenza |
Influenza A virus |
Mice became protected |
[59]. |
|
Swine fever |
Classical swine fever virus |
Neutralising antibodies induced in pigs |
[60] |
CIGB-228 |
Cervical intraepithelial neoplasia |
Human papilloma virus |
Lesion regression and HPV clearance |
[61]. |
IMPIPS |
Malaria |
Plasmodium falciparum |
Aotus monkeys became protected |
[62,63] |